Forward Management Decreased Taiwan Semiconductor Mfg LTD (TSM) Stake By $471,978; Five Prime Therapeutics Has 1.34 Sentiment

May 22, 2018 - By Michael Collier

Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) Logo

Forward Management Llc decreased Taiwan Semiconductor Mfg Ltd (TSM) stake by 8.37% reported in 2017Q4 SEC filing. Forward Management Llc sold 12,102 shares as Taiwan Semiconductor Mfg Ltd (TSM)’s stock rose 9.24%. The Forward Management Llc holds 132,527 shares with $5.25 million value, down from 144,629 last quarter. Taiwan Semiconductor Mfg Ltd now has $199.55 billion valuation. The stock increased 0.47% or $0.185 during the last trading session, reaching $39.655. About 1.54 million shares traded. Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) has risen 30.51% since May 22, 2017 and is uptrending. It has outperformed by 18.96% the S&P500.

Five Prime Therapeutics Inc (FPRX) investors sentiment increased to 1.34 in Q4 2017. It’s up 0.30, from 1.04 in 2017Q3. The ratio has increased, as 67 institutional investors increased and started new equity positions, while 50 trimmed and sold holdings in Five Prime Therapeutics Inc. The institutional investors in our database now own: 25.47 million shares, up from 23.96 million shares in 2017Q3. Also, the number of institutional investors holding Five Prime Therapeutics Inc in top ten equity positions was flat from 0 to 0 for the same number . Sold All: 21 Reduced: 29 Increased: 43 New Position: 24.

More news for Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) were recently published by: Fool.com, which released: “Why TSMC Is a Top Stock to Buy in May” on May 11, 2018. Fool.com‘s article titled: “Better Buy: TSMC vs. Qualcomm, Inc.” and published on May 14, 2018 is yet another important article.

Analysts await Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) to report earnings on July, 12. They expect $0.45 EPS, up 7.14% or $0.03 from last year’s $0.42 per share. TSM’s profit will be $2.26B for 22.03 P/E if the $0.45 EPS becomes a reality. After $0.59 actual EPS reported by Taiwan Semiconductor Manufacturing Company Limited for the previous quarter, Wall Street now forecasts -23.73% negative EPS growth.

Among 8 analysts covering Taiwan Semiconductor Manufacturing (NYSE:TSM), 4 have Buy rating, 0 Sell and 4 Hold. Therefore 50% are positive. Taiwan Semiconductor Manufacturing had 17 analyst reports since August 24, 2015 according to SRatingsIntel. On Tuesday, October 10 the stock rating was upgraded by J.P. Morgan to “Buy”. The company was downgraded on Thursday, October 13 by HSBC. The firm has “Outperform” rating by Credit Suisse given on Friday, December 11. As per Tuesday, March 13, the company rating was maintained by Susquehanna. The stock of Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) has “Buy” rating given on Monday, January 22 by Goldman Sachs. The firm has “Neutral” rating given on Tuesday, October 4 by Susquehanna. Pacific Crest upgraded the shares of TSM in report on Friday, October 14 to “Sector Weight” rating. The stock has “Hold” rating by Susquehanna on Thursday, April 19. As per Thursday, January 18, the company rating was maintained by Susquehanna. The rating was downgraded by Goldman Sachs to “Neutral” on Tuesday, June 28.

The stock increased 2.31% or $0.4305 during the last trading session, reaching $19.1005. About 80,747 shares traded. Five Prime Therapeutics, Inc. (FPRX) has declined 52.34% since May 22, 2017 and is downtrending. It has underperformed by 63.89% the S&P500.

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics in the United States. The company has market cap of $672.52 million. The companyÂ’s product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor, as well as conducts Phase I clinical trials for the treatment of rheumatoid arthritis. It currently has negative earnings. The Company’s product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor IIb and is in Phase I clinical trials to treat patients with gastric cancer; and FP-1039, a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors.

Analysts await Five Prime Therapeutics, Inc. (NASDAQ:FPRX) to report earnings on August, 14. They expect $-1.33 earnings per share, up 15.82% or $0.25 from last year’s $-1.58 per share. After $-0.63 actual earnings per share reported by Five Prime Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 111.11% negative EPS growth.

Awm Investment Company Inc. holds 0.64% of its portfolio in Five Prime Therapeutics, Inc. for 150,000 shares. Bb Biotech Ag owns 827,500 shares or 0.51% of their US portfolio. Moreover, Rock Springs Capital Management Lp has 0.42% invested in the company for 425,000 shares. The Massachusetts-based Eventide Asset Management Llc has invested 0.36% in the stock. Granite Point Capital Management L.P., a Massachusetts-based fund reported 80,000 shares.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: